Get the Stockscreener App
0.292
0.76%
+0.0022
60 Degrees Pharmaceuticals Inc stock is currently priced at $0.292, with a 24-hour trading volume of 353.58K.
It has seen a +0.76% increased in the last 24 hours and a +27.07% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.2843 pivot point. If it approaches the $0.3035 resistance level, significant changes may occur.
Previous Close:
$0.2898
Open:
$0.294
24h Volume:
353.58K
Market Cap:
$3.55M
Revenue:
$90,700
Net Income/Loss:
$-3.43M
P/E Ratio:
-0.1795
EPS:
-1.6266
Net Cash Flow:
$-4.65M
1W Performance:
-7.27%
1M Performance:
+27.07%
6M Performance:
-52.90%
1Y Performance:
+0.00%
1D Range:
$0.2735
$0.2978
52W Range:
$0.2011
$1.53
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
Name
60 Degrees Pharmaceuticals Inc
Sector
Industry
Phone
202-327-5422
Address
1025 Connecticut Avenue NW, Suite 1000, Washington
60 Degrees Pharmaceuticals Inc Stock (SXTP) Latest News
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center ... - GlobeNewswire
GlobeNewswire
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center ... - Yahoo Finance
Yahoo Finance
60 Degrees Pharmaceuticals Inc (SXTP) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
The InvestChronicle
60 Degrees Pharmaceuticals Inc (SXTP) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
The InvestChronicle
Quarterly Snapshot: Quick and Current Ratios for 60 Degrees Pharmaceuticals Inc (SXTP) – DWinneX - The Dwinnex
The Dwinnex
It makes sense and dollars to buy 60 Degrees Pharmaceuticals Inc (SXTP) stock – Sete News - SETE News
SETE News
60 Degrees Pharmaceuticals Inc Stock (SXTP) Financials Data
60 Degrees Pharmaceuticals Inc (SXTP) Revenue 2024
SXTP reported a revenue (TTM) of $90.70 thousand for the quarter ending September 30, 2023, a -68.70% decline year-over-year.
60 Degrees Pharmaceuticals Inc (SXTP) Net Income 2024
SXTP net income (TTM) was -$3.43 million for the quarter ending September 30, 2023, a +41.57% increase year-over-year.
60 Degrees Pharmaceuticals Inc (SXTP) Cash Flow 2024
SXTP recorded a free cash flow (TTM) of -$4.65 million for the quarter ending September 30, 2023.
60 Degrees Pharmaceuticals Inc (SXTP) Earnings per Share 2024
SXTP earnings per share (TTM) was -$0.5967 for the quarter ending September 30, 2023, a +43.36% growth year-over-year.
60 Degrees Pharmaceuticals Inc Stock (SXTP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Allen Charles W | Director |
May 16 '24 |
Option Exercise |
0.22 |
4,000 |
892 |
14,000 |
| FIELD PAUL | Director |
May 16 '24 |
Option Exercise |
0.22 |
4,000 |
892 |
14,000 |
| XU CHERYL | Director |
May 16 '24 |
Option Exercise |
0.22 |
2,000 |
446 |
228,934 |
| DOW GEOFFREY S | President and CEO |
Apr 12 '24 |
Option Exercise |
0.27 |
68,000 |
18,142 |
745,625 |
| XU CHERYL | Director |
Jan 31 '24 |
Buy |
0.38 |
200,000 |
75,000 |
424,934 |
| DOW GEOFFREY S | President and CEO |
Jan 31 '24 |
Buy |
0.38 |
25,974 |
9,740 |
703,599 |
About 60 Degrees Pharmaceuticals Inc
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
0.79%
3.50%
Cap:
|
Volume (24h):